Pfizer touts monthly injectable PF‑3944 as practical obesity challenger amid Trump drug pricing push

Pfizer targets monthly injectable as a practical challenger in obesity market

Pfizer is positioning its long-acting injectable PF′3944 as a potential game-changer in obesity treatment after releasing mid-stage data showing up to 12.3% greater weight loss versus placebo at week 28. The company is presenting results in June and says the regimen, which starts with 12 weeks of weekly injections before switching to monthly dosing, shows no plateau after the switch and continues to drive weight loss through the planned 64-week study period. Pfizer is highlighting tolerability and convenience as differentiators against weekly GLP‑1 injectables and new oral entrants.

The drug follows Pfizer’s roughly $10 billion Metsera acquisition and signals the company’s renewed push into the obesity space, where market leadership is held by Eli Lilly and Novo Nordisk. CEO Albert Bourla characterises the candidate as having a “very competitive profile in tolerability and efficacy,” and company modelling suggests a higher phase‑3 dose could produce roughly 16% weight loss at week 28. Pfizer plans to launch ten phase‑3 trials aimed at potential approvals in 2028, including studies that allow patients on existing weekly GLP‑1 therapies to switch to PF′3944 as a maintenance option.

Company executives stress trial design priorities that include diverse patient enrolment, higher dose testing, longer safety follow‑up and switch trials from current therapies. They say regulatory timelines and commercial positioning will hinge on the full June readout and subsequent phase‑3 outcomes. The emphasis on monthly dosing and a robust tolerability profile aims to address adherence and convenience, two commercial levers Pfizer intends to use to capture share in a rapidly evolving obesity treatment market.

White House roll-out draws industry attention

Separately, the Trump administration launches TrumpRx.gov, a government‑backed website meant to give consumers access to discounted drugs under most‑favoured‑nation style pricing deals. President Donald Trump says 16 of the 17 largest drugmakers have agreed to extend low Medicaid prices to cash‑paying consumers; media coverage of the launch references Pfizer among the companies being watched by policymakers.

Price push prompts questions over innovation

The initiative pairs pricing concessions with tariff exemptions and seeks dramatic price reductions, which administration officials say will reduce U.S. drug costs relative to other countries. Pharmaceutical executives, including at Pfizer, are monitoring potential impacts on pricing, investment and innovation as the policy unfolds and as public concern about healthcare costs intensifies.